Reversal of diabetes in NOD Mice by clinical-grade proinsulin and IL-10'secreting lactococcus lactis in combination with low-dose Anti-CD3 depends on the induction of Foxp3-Positive T Cells

Diabetes

Volumn 66, Issue 2, 2017, Pages 448-459

  Takiishi, Tatiana ^a   Cook, Dana Paulina ^a   Korf, Hannelie ^a   Sebastiani, Guido ^b   Mancarella, Francesca ^b   Cunha, João Paulo Monteiro Carvalho Mori ^a   Wasserfall, Clive ^c   Casares, Noelia ^d   Lasarte, Juan José ^d   Steidler, Lothar ^e   Rottiers, Pieter ^e   Dotta, Francesco ^b   Gysemans, Conny ^a   Mathieu, Chantal ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

^e INTREXON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CD3 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; INTERLEUKIN 10; LACTOCOCCUS LACTIS VACCINE; PROINSULIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIBODY; CD3 ANTIGEN; CTLA4 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS; FLOW CYTOMETRY; FOLLOW UP; FUNCTIONAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; INSULITIS; LOW DRUG DOSE; LYMPH NODE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; CD4+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; LACTOBACILLUS; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BLOOD GLUCOSE; CD3 COMPLEX; CD4-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE TOLERANCE TEST; IMMUNE TOLERANCE; INTERLEUKIN-10; LACTOBACILLUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; PANCREAS; PROINSULIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 85011661866     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1625     Document Type: Article

References (35)

1. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076
2. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327
3. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012;366:433-442
4. Culina S, Boitard C, Mallone R. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol 2011;2011:286248
5. Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann N Y Acad Sci 2006;1072:176-186
6. Robert S, Steidler L. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case. Microb Cell Fact 2014;13(Suppl. 1):S11
7. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITNJDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010;160:176-184
8. Robert S, Korf H, Gysemans C, Mathieu C. Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets 2013;5:53-66
9. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012;122:1717-1725
10. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003;21:785-789
11. Robert S, Gysemans C, Takiishi T, et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 2014;63:2876-2887
12. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009;31:654-664
13. Tian L, Altin JA, Makaroff LE, et al. Foxp3+ regulatory T cells exert asymmetric control over murine helper responses by inducing Th2 cell apoptosis. Blood 2011;118:1845-1853
14. Casares N, Rudilla F, Arribillaga L, et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 2010; 185:5150-5159
15. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8: 191-197
16. Suffner J, Hochweller K, Kühnle MC, et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J Immunol 2010;184:1810-1820
17. Mayer CT, Lahl K, Milanez-Almeida P, et al. Advantages of Foxp3(+) regulatory T cell depletion using DEREG mice. Immun Inflamm Dis 2014;2:162-165
18. Commins SP. Mechanisms of Oral Tolerance. Pediatr Clin North Am 2015; 62:1523-1529
19. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497
20. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-Antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352: 2598-2608
21. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013;56:391-400
22. Demeester S, Keymeulen B, Kaufman L, et al. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual b-cell function in recent-onset type 1 diabetes. Diabetes Care 2015;38:644-651
23. Sojka DK, Hughson A, Fowell DJ. CTLA-4 is required by CD4+CD25+ Treg to control CD4+ T-cell lymphopenia-induced proliferation. Eur J Immunol 2009; 39:1544-1551
24. Balkow S, Heinz S, Schmidbauer P, et al. LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. Blood 2010;116:1885-1894
25. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014;14:154-165
26. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004;34:2996-3005
27. Wing K, Yamaguchi T, Sakaguchi S. Cell-Autonomous and-non-Autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011;32:428-433
28. Tran DQ. TGF-b: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 2012;4:29-37
29. Selvaraj RK, Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol 2007;178:7667-7677
30. Maynard CL, Harrington LE, Janowski KM, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3-precursor cells in the absence of interleukin 10. Nat Immunol 2007;8:931-941
31. Fowler S, Powrie F. CTLA-4 expression on antigen-specific cells but not IL-10 secretion is required for oral tolerance. Eur J Immunol 2002;32:2997-3006
32. Pletinckx K, Döhler A, Pavlovic V, Lutz MB. Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells. Front Immunol 2011;2:39
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061
34. Mayer CT, Ghorbani P, Kühl AA, et al. Few Foxp3+ regulatory T cells are sufficient to protect adult mice from lethal autoimmunity. Eur J Immunol 2014; 44:2990-3002
35. Alissafi T, Hatzioannou A, Ioannou M, et al. De novo-induced selfantigen-specific Foxp3+ regulatory T cells impair the accumulation of inflammatory dendritic cells in draining lymph nodes. J Immunol 2015; 194:5812-5824